Sam Blackman
Person ● Covered in 0 stories + Follow ✴ AI Graph Request update
Sam Blackman is Entrepreneur in Residence at GV, where he joined in 2025. He is a physician-scientist, pediatric neuro-oncologist, and cancer drug developer who trained at the University of Illinois at Chicago, Cincinnati Children’s Hospital, Dana-Farber Cancer Institute, Boston Children’s Hospital, and Harvard Medical School after earlier clinical research work in anesthesia and critical care medicine. He later moved into oncology drug development, holding senior roles at Merck, GlaxoSmithKline, Seattle Genetics, Juno Therapeutics, Silverback Therapeutics, and Mavupharma before co-founding Day One Biopharmaceuticals in 2018 and serving as Chief Medical Officer and Head of Research & Development. He is known for leading early clinical development of multiple cancer therapeutics, including the pediatric program for dabrafenib, and for helping guide Day One’s tovorafenib (OJEMDA) to FDA approval in 2024 for childhood brain tumors.
Updated 4 September 2026
Public sources: gv.com
Why this page exists, and how to correct or remove it
This profile is assembled automatically because Sam Blackman appears in coverage we index or holds a role listed publicly by their organisation. It uses only public sources — company and organisation pages, news articles, Wikipedia, and public professional listings — and the biography, if any, is written by AI from those sources and cited above.
We hold it to report on the AI industry, under the legitimate interest of journalistic reporting. You can ask us to correct it, restrict it, or take it down, and you can object at any time — no account needed, no reason required.
Claim or correct this profile Request removal How we handle personal data